Literature DB >> 8116338

Effects of neuropsychological treatment in patients with multiple sclerosis.

A Jønsson1, E M Korfitzen, A Heltberg, M H Ravnborg, E Byskov-Ottosen.   

Abstract

The chronic and progressive nature of multiple sclerosis (MS) often excludes patients from neuropsychological treatment. At the Multiple Sclerosis Rehabilitation Hospital, Haslev, 40 patients with mild to moderate cognitive and behavioral impairment associated with MS were randomized to either specific cognitive treatment (20 pts) by direct training, compensatory strategies and neuropsychotherapy, or to non-specific, deliberately diffuse mental stimulation (20 pts). Treatment was for a mean of 46 days. The effects of treatment were evaluated by neuropsychological tests before treatment, immediately after treatment (short-term effects) and 6 months later (long-term effects). After short-term treatment, effects on cognitive measures were not convincing, but on the Beck Depression Inventory (BDI) the specific cognitive treatment group reported significantly less depression. After 6 months only this group showed an effect, since the visuo-spatial memory was improved. However, the depression ratings (BDI) were almost maintained from the short-term level. Interestingly, the non-specific treatment group rated themselves as significantly more depressed. Conclusively, it is worth while to offer specific neuropsychological treatment to MS patients with cognitive and behavioral dysfunction.

Entities:  

Mesh:

Year:  1993        PMID: 8116338     DOI: 10.1111/j.1600-0404.1993.tb05366.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  18 in total

Review 1.  Neuropsychological rehabilitation in adult multiple sclerosis.

Authors:  F Mattioli; C Stampatori; F Bellomi; R Capra; M Rocca; M Filippi
Journal:  Neurol Sci       Date:  2010-11       Impact factor: 3.307

Review 2.  [Cognitive dysfunctions in multiple sclerosis patients].

Authors:  C Engel; B Greim; U K Zettl
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

3.  Cognition and physical disability in predicting health-related quality of life in multiple sclerosis.

Authors:  Marietta Hoogs; Sukhmit Kaur; Audrey Smerbeck; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  Int J MS Care       Date:  2011

4.  Computer assisted retraining of attentional impairments in patients with multiple sclerosis.

Authors:  A M Plohmann; L Kappos; W Ammann; A Thordai; A Wittwer; S Huber; Y Bellaiche; J Lechner-Scott
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

5.  Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis.

Authors:  N B Lincoln; A Dent; J Harding; N Weyman; C Nicholl; L D Blumhardt; E D Playford
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 6.  Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

Authors:  Bridget Bagert; Patricia Camplair; Dennis Bourdette
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 7.  Neuropsychological aspects of multiple sclerosis.

Authors:  J C Brassington; N V Marsh
Journal:  Neuropsychol Rev       Date:  1998-06       Impact factor: 7.444

Review 8.  Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?

Authors:  Christopher Christodoulou; William S MacAllister; Nancy A McLinskey; Lauren B Krupp
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis.

Authors:  Iris-Katharina Penner; Klaus Opwis; Ludwig Kappos
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

Review 10.  Cognitive impairment in multiple sclerosis.

Authors:  Alexander Winkelmann; Claudia Engel; Annett Apel; Uwe K Zettl
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.